TCGA-A2-A1G4-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 20
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.440
- PROTEIN_SECRETION+0.370
- MYC_TARGETS_V1+0.360
- MITOTIC_SPINDLE+0.270
- ESTROGEN_RESPONSE_EARLY+0.240
- DNA_REPAIR+0.220
- MTORC1_SIGNALING+0.210
- ESTROGEN_RESPONSE_LATE+0.200
- ANDROGEN_RESPONSE+0.190
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.450
- ALLOGRAFT_REJECTION-0.380
- MYOGENESIS-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- COAGULATION-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.901 |
| 2 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.900 |
| 3 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.851 |
| 4 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.850 |
| 5 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.848 |
| 6 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.847 |
| 7 | TCGA-E9-A228-01A-31R-A157-07 | — | B | 0.847 |
| 8 | R360 | — | — | 0.846 |
| 9 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.845 |
| 10 | SRR33532819 | — | E | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |